Dutch Cancer Society

The Inner Circle Acknowledges, Pierre-Yves Sonke, MD as a Top Pinnacle Healthcare Professional for his contributions to Medical Imaging

Retrieved on: 
Monday, August 14, 2023

TARRYTOWN, N.Y., Aug. 14, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Pierre-Yves Sonke, MD, is acknowledged as a Top Pinnacle Healthcare Professional for his contributions to Medical Imaging.

Key Points: 
  • TARRYTOWN, N.Y., Aug. 14, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Pierre-Yves Sonke, MD, is acknowledged as a Top Pinnacle Healthcare Professional for his contributions to Medical Imaging.
  • He is considered a specialist, including body imaging; nuclear medicine; PET/CT; body CT; MR and ultrasound imaging.
  • According to the doctor, diagnostic radiology refers to the field of medicine that uses non-invasive imaging scans for medical diagnosis.
  • In addition to his medical practice, Dr. Sonke is an assistant professor of radiology at New York Medical College.

Press Release: KPN nominates Marga de Jager to Supervisory Board

Retrieved on: 
Saturday, April 15, 2023

KPN's Supervisory Board is pleased to announce the nomination of Ms Marga de Jager for appointment to the Supervisory Board.

Key Points: 
  • KPN's Supervisory Board is pleased to announce the nomination of Ms Marga de Jager for appointment to the Supervisory Board.
  • Marga de Jager will succeed Chantal Vergouw who recently has been nominated as a member of the Board of Management responsible for Business Market.
  • Marga de Jager (54, Dutch) is a seasoned executive with broad experience in the private and public domain.
  • Ms De Jager chairs the Supervisory Board of ANWB’s insurance company Unigarant, as well as the Mobility Alliance.

Cancer Research Initiative Announces Funding for Global Research Community to Take on Nine of Cancer’s Toughest Challenges

Retrieved on: 
Wednesday, March 8, 2023

Cancer Grand Challenges, a research initiative co-founded by Cancer Research UK and the National Cancer Institute (NCI), today announced nine new challenges for the global research community to take on – representing obstacles that continue to impede progress against cancer and, ultimately, benefits for patients.

Key Points: 
  • Cancer Grand Challenges, a research initiative co-founded by Cancer Research UK and the National Cancer Institute (NCI), today announced nine new challenges for the global research community to take on – representing obstacles that continue to impede progress against cancer and, ultimately, benefits for patients.
  • Cancer Grand Challenges unites the world's brightest minds across boundaries and disciplines to tackle cancer's most complex challenges.
  • In support of Cancer Grand Challenges, Cancer Research UK is building a global network of partners, including the Dutch Cancer Society, The Mark Foundation for Cancer Research and Scientific Foundation of the Spanish Association Against Cancer.
  • Cancer Grand Challenges provides an unparalleled opportunity for the world’s scientific community to come together and make change”, said Dr. David Scott, Director of Cancer Grand Challenges.

Oncode Institute and ArgoBio Launch Laigo Bio, a Targeted Protein Degradation Biotech With Programs in Oncology and Neurological Disorders

Retrieved on: 
Tuesday, February 8, 2022

ArgoBio and Oncode Institute have teamed up with Oncode Investigator Madelon Maurice , researcher and group leader at UMC Utrecht, to launch Laigo Bio, a new company in the emerging field of target protein degradation.

Key Points: 
  • ArgoBio and Oncode Institute have teamed up with Oncode Investigator Madelon Maurice , researcher and group leader at UMC Utrecht, to launch Laigo Bio, a new company in the emerging field of target protein degradation.
  • The company has additionally secured funding from Oncode Bridge Fund and ArgoBio to further develop its proprietary pipeline of targeted immunotherapies SureTACsR.
  • The SureTACsR technology platform is a novel approach in membrane protein degradation, applicable to a broad scope of disease applications.
  • The primary focus lies in the area of oncology, but with parallel programs in neuro-inflammation and neuro degenerative diseases.

DGAP-News: HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination ther

Retrieved on: 
Wednesday, October 20, 2021

MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers.

Key Points: 
  • MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers.
  • This new and unique therapeutic concept was discovered by Prof. Lars Zender and his research group at the University Hospital Tubingen, Germany.
  • Investors in HepaRegeniX include the Boehringer Ingelheim Venture Fund (BIVF), Novo Holdings A/S, Coparion, High-Tech Gruenderfonds and Ascenion GmbH.
  • About the Netherlands Cancer Institute, Amsterdam - www.nki.nl
    The Netherlands Cancer Institute , founded in 1913, is among the world's best comprehensive cancer centers, combining world-class fundamental, translational, and clinical research with dedicated patient care.

Lixte Biotechnology Announces Collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to Identify the Most Promising Drug Combinations for its Lead Clinical Compound, LB-100, for Cancer Treatment

Retrieved on: 
Wednesday, October 13, 2021

Its ubiquitous activity and low toxicity have made it challenging to select the most promising clinical targets for this novel compound.

Key Points: 
  • Its ubiquitous activity and low toxicity have made it challenging to select the most promising clinical targets for this novel compound.
  • Professor Bernards commented, We are excited to work with Lixte to identify the most powerful drug combinations of LB-100 for cancer therapy.
  • Our unbiased genetic approach to identify synthetic lethal drug targets of LB-100 has proven its utility in our previous studies.
  • www.lixte.com
    About the Netherlands Cancer Institute, Amsterdam
    The Netherlands Cancer Institute , founded in 1913, is among the worlds best comprehensive cancer centers, combining world-class fundamental, translational, and clinical research with dedicated patient care.